risks of glp 1 agonists The cardiovascular effects GLP-1 receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action America's Poison Centers - GLP-1
Description
Neuropeptides (2018) 71:7080
CK, through the reduction of TGF1 and inhibiting its downstream pathway, RhoA/ROCK, ameliorates the G/F-actin ratio, which under glucotoxicity creates a barrier for GLP-1 secretion
doi: 10.1152/ajpendo.00460.2009
Yanovski, J.A
